Charles Theuer - Apr 26, 2023 Form 4 Insider Report for Tracon Pharmaceuticals, Inc. (TCON)

Role: President and CEO, Director
Signature: /s/ Scott B. Brown, Attorney-in-Fact
Stock symbol: TCON
Transactions as of: Apr 26, 2023
Transactions value $: $37,889
Form type: 4
Date filed: 4/28/2023, 06:00 AM
Previous filing: Mar 2, 2023
Next filing: May 25, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TCON	Common Stock	Purchase	$2.64K	+4K	+1.15%	$0.66	352K	Apr 26, 2023	Direct	F1
transaction	TCON	Common Stock	Purchase	$35.3K	+47K	+13.34%	$0.75	399K	Apr 27, 2023	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 3,500 shares acquired by the Reporting Person under the Issuer's 2015 Employee Stock Purchase Plan on April 20, 2023.
F2	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.72 to $0.7596, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Content

Includes 3,500 shares acquired by the Reporting Person under the Issuer's 2015 Employee Stock Purchase Plan on April 20, 2023.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.72 to $0.7596, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.